Literature DB >> 1355850

Acute changes in growth hormone-releasing hormone secretion after injection of BIM 23014, a long acting somatostatin analog, in rams.

E Magnan1, M Cataldi, V Guillaume, B Conte-Devolx, N Graziani, J C Figaroli, F Thomas, K Chihara, C Oliver.   

Abstract

BIM 23014 is a somatostatin analog displaying an increased biological half life due to resistance to enzymatic degradation. This peptide inhibits GH release directly at the level of pituitary somatotrophs. In addition, an action of BIM 23014 at the level of the hypothalamus is possible since somatostatinergic fibers and receptors have been identified on GH-RH neurons. To evaluate the effect of BIM 23014 on GH-RH secretion, hypophysial portal blood (HPB) was continuously collected in conscious sheep. Twelve rams (40-45 kg, 9-month-old) with chronically implanted perihypophysial cannulae were i.v. injected with BIM 23014 (1 mg) or saline. HPB and jugular blood were collected for 3-5 hours before and after the injection for the determinations of GH-RH and GH concentrations respectively. The acute injection of BIM 23014 induced a rapid decrease of plasma GH within the first two hours. Simultaneously, GH-RH in HPB decreased significantly. After reaching a nadir, GH concentrations increased to values greater than baseline. A similar rebound in GH-RH levels in HPB was also observed. These data indicate that BIM 23014 acts at the level of GH-RH hypothalamic neurons, in addition to its well-know effect on the pituitary gland.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355850     DOI: 10.1016/0024-3205(92)90610-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Gender modulates sequential suppression and recovery of pulsatile growth hormone secretion by physiological feedback signals in young adults.

Authors:  Johannes D Veldhuis; Leon Farhy; Arthur L Weltman; Jonathan Kuipers; Judith Weltman; Laurie Wideman
Journal:  J Clin Endocrinol Metab       Date:  2005-02-22       Impact factor: 5.958

2.  Relationship between hypophyseal portal GHRH and somatostatin and peripheral GH levels in the conscious sheep.

Authors:  M Cataldi; E Magnan; V Guillaume; A Dutour; B Conte-Devolx; G Lombardi; C Oliver
Journal:  J Endocrinol Invest       Date:  1994-10       Impact factor: 4.256

3.  Complex regulation of GH autofeedback under dual-peptide drive: studies under a pharmacological GH and sex steroid clamp.

Authors:  Johannes D Veldhuis; Dana Erickson; John M Miles; Cyril Y Bowers
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-04-05       Impact factor: 4.310

4.  Complementary secretagogue pairs unmask prominent gender-related contrasts in mechanisms of growth hormone pulse renewal in young adults.

Authors:  Cacia Soares-Welch; Leon Farhy; Kristi L Mielke; Farid H Mahmud; John M Miles; Cyril Y Bowers; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2005-01-05       Impact factor: 5.958

5.  Endogenous Estrogen Regulates Somatostatin-Induced Rebound GH Secretion in Postmenopausal Women.

Authors:  Johannes D Veldhuis; Dana Erickson; Rebecca Yang; Paul Takahashi; Cyril Bowers
Journal:  J Clin Endocrinol Metab       Date:  2016-07-26       Impact factor: 5.958

6.  Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies in men during experimental hypogonadal clamp.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Joy N Bailey; Adebordurin M Adeniji; John M Miles; Cyril Y Bowers
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

7.  Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli.

Authors:  C A Jaffe; R DeMott-Friberg; A L Barkan
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.